A Study to Examine the Relationship Between CEO Characteristics and Organizational Performance in the U.S. Pharmaceutical and Biopharmaceutical Industries- [electronic resource]
A Study to Examine the Relationship Between CEO Characteristics and Organizational Performance in the U.S. Pharmaceutical and Biopharmaceutical Industries- [electronic resource]
- 자료유형
- 학위논문파일 국외
- 최종처리일시
- 20240214101214
- ISBN
- 9798380306935
- DDC
- 362.1
- 서명/저자
- A Study to Examine the Relationship Between CEO Characteristics and Organizational Performance in the U.S. Pharmaceutical and Biopharmaceutical Industries - [electronic resource]
- 발행사항
- [S.l.]: : The University of Alabama at Birmingham., 2023
- 발행사항
- Ann Arbor : : ProQuest Dissertations & Theses,, 2023
- 형태사항
- 1 online resource(117 p.)
- 주기사항
- Source: Dissertations Abstracts International, Volume: 85-03, Section: B.
- 주기사항
- Advisor: Borkowski, Nancy.
- 학위논문주기
- Thesis (D.Sc.)--The University of Alabama at Birmingham, 2023.
- 사용제한주기
- This item must not be sold to any third party vendors.
- 초록/해제
- 요약This study examined the relationship between CEO tenure, sex, level of education, and organizational performance across 229 U.S. publicly traded pharmaceutical and biopharmaceutical companies. The Upper Echelons Theory was used to guide this research on how CEO characteristics could impact organizational performance. Fifteen hypotheses were developed and tested to evaluate the statistically significant relationship between CEO tenure, sex, level of education, and the organizational performance demonstrated in the abnormal stock return valuation and the number of FDA-approved drug products in clinical trial phases (phase 1, 2, and 3) for each company.This quantitative, non-experimental, and cross-sectional study was completed by conducting Multiple Linear Regression analysis and Negative Binomial Regression analysis to quantitative secondary data representing CEOs' characteristics and their organizations.Study findings suggest that the length of CEO tenure had a positive statistically significant relationship with organizational performance. Our results showed that as a CEO's tenure increases by one year, the abnormal stock return increases by 0.92%, and the number of drug products in the pipeline in phase 3 increases by a factor of 1.03 (3%). CEO sex and level of education did not indicate any statistically significant relationship with the abnormal stock return or the number of FDA-approved drug products in clinical trial phases (phases 1, 2, and 3).
- 일반주제명
- Health care management.
- 기타저자
- The University of Alabama at Birmingham Administration/Health Services
- 기본자료저록
- Dissertations Abstracts International. 85-03B.
- 기본자료저록
- Dissertation Abstract International
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
